miR-657 Targets SRCIN1 via the Slug Pathway to Promote NSCLC Tumor Growth and EMT Induction

Table 1

Correlation between miR-657 expression and clinicopathological features in NSCLC patients.

Parameters	Group		Expression of miR-657		value
			Low, (%)	High, (%)
Age (years)	≤58	46	22 (48.83)	24 (52.17)	0.6828
	>58	50	26 (52.00)	24 (48.00)
Gender	Female	48	26 (54.17)	22 (45.83)	0.8374
	Male	48	27 (56.25)	21 (43.75)
Tumor size (cm)	<3	40	17 (66.67)	23 (33.33)	0.2847
	≥3	56	30 (34.38)	26 (65.62)
TNM stage	I–II	52	38 (73.08)	14 (26.92)	0.0003
	III–IV	44	16 (36.36)	28 (63.64)
Smoking history	Yes	46	27 (58.70)	19 (41.30)	0.8966
	No	50	30 (60.00)	20 (40.00)
Lymph node metastasis	Yes	42	14 (33.33)	28 (66.67)	0.0040
	No	54	34 (62.96)	20 (37.04)
Differentiation	Well/moderate	47	32 (68.09)	15 (31.91)	0.0021
	Poor	49	18 (36.73)	31 (63.27)
Subtypes	Squamous carcinoma	27	12 (44.44)	15 (55.56)	0.2536
	Adenomatous carcinoma	21	14 (66.67)	7 (33.33)
	Adenosquamous carcinoma	26	10 (38.46)	16 (61.54)
	Magnocellular carcinoma	22	10 (45.45)	12 (54.55)